EG22506A - Processes and intermediates for preparing anti-cancer compounds - Google Patents

Processes and intermediates for preparing anti-cancer compounds

Info

Publication number
EG22506A
EG22506A EG20000364A EG20000364A EG22506A EG 22506 A EG22506 A EG 22506A EG 20000364 A EG20000364 A EG 20000364A EG 20000364 A EG20000364 A EG 20000364A EG 22506 A EG22506 A EG 22506A
Authority
EG
Egypt
Prior art keywords
intermediates
processes
preparing anti
cancer compounds
cancer
Prior art date
Application number
EG20000364A
Other languages
English (en)
Inventor
Richard S Lehner
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Application granted granted Critical
Publication of EG22506A publication Critical patent/EG22506A/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
    • C07D239/94—Nitrogen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic Table
    • C07F7/02—Silicon compounds
    • C07F7/08—Compounds having one or more C—Si linkages
    • C07F7/0803—Compounds with Si-C or Si-Si linkages
    • C07F7/081—Compounds with Si-C or Si-Si linkages comprising at least one atom selected from the elements N, O, halogen, S, Se or Te
    • C07F7/0812—Compounds with Si-C or Si-Si linkages comprising at least one atom selected from the elements N, O, halogen, S, Se or Te comprising a heterocyclic ring
    • C—CHEMISTRY; METALLURGY
    • C22—METALLURGY; FERROUS OR NON-FERROUS ALLOYS; TREATMENT OF ALLOYS OR NON-FERROUS METALS
    • C22B—PRODUCTION AND REFINING OF METALS; PRETREATMENT OF RAW MATERIALS
    • C22B15/00—Obtaining copper
    • C22B15/0002—Preliminary treatment
    • C22B15/0004—Preliminary treatment without modification of the copper constituent
    • C—CHEMISTRY; METALLURGY
    • C22—METALLURGY; FERROUS OR NON-FERROUS ALLOYS; TREATMENT OF ALLOYS OR NON-FERROUS METALS
    • C22B—PRODUCTION AND REFINING OF METALS; PRETREATMENT OF RAW MATERIALS
    • C22B15/00—Obtaining copper
    • C22B15/0063—Hydrometallurgy
    • C22B15/0065—Leaching or slurrying
    • C22B15/0067—Leaching or slurrying with acids or salts thereof
    • C22B15/0071—Leaching or slurrying with acids or salts thereof containing sulfur
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P10/00—Technologies related to metal processing
    • Y02P10/20—Recycling

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Health & Medical Sciences (AREA)
  • Mechanical Engineering (AREA)
  • Manufacturing & Machinery (AREA)
  • Metallurgy (AREA)
  • Materials Engineering (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
EG20000364A 1999-03-31 2000-03-27 Processes and intermediates for preparing anti-cancer compounds EG22506A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US12707299P 1999-03-31 1999-03-31

Publications (1)

Publication Number Publication Date
EG22506A true EG22506A (en) 2003-03-31

Family

ID=22428179

Family Applications (1)

Application Number Title Priority Date Filing Date
EG20000364A EG22506A (en) 1999-03-31 2000-03-27 Processes and intermediates for preparing anti-cancer compounds

Country Status (50)

Country Link
US (1) US6476040B1 (hu)
EP (1) EP1044969B1 (hu)
JP (2) JP3420549B2 (hu)
KR (2) KR100430210B1 (hu)
CN (2) CN100351242C (hu)
AP (2) AP1655A (hu)
AR (1) AR018705A1 (hu)
AT (1) ATE348098T1 (hu)
AU (2) AU781402B2 (hu)
BG (1) BG65194B1 (hu)
BR (1) BRPI0001486B8 (hu)
CA (2) CA2302965C (hu)
CO (1) CO5160273A1 (hu)
CR (1) CR6165A (hu)
CZ (1) CZ299426B6 (hu)
DE (1) DE60032275T2 (hu)
DK (1) DK1044969T3 (hu)
DZ (1) DZ3030A1 (hu)
EA (3) EA004654B1 (hu)
EE (1) EE04589B1 (hu)
EG (1) EG22506A (hu)
ES (1) ES2278578T3 (hu)
GE (1) GEP20022653B (hu)
GT (1) GT200000037A (hu)
HK (1) HK1029790A1 (hu)
HR (1) HRP20000182B1 (hu)
HU (1) HU227698B1 (hu)
ID (1) ID25427A (hu)
IL (2) IL135245A0 (hu)
IS (1) IS2468B (hu)
MA (1) MA25087A1 (hu)
MY (1) MY136270A (hu)
NO (2) NO321952B1 (hu)
NZ (2) NZ503683A (hu)
OA (1) OA11335A (hu)
PA (1) PA8491901A1 (hu)
PE (1) PE20001599A1 (hu)
PL (1) PL339330A1 (hu)
PT (1) PT1044969E (hu)
RS (1) RS49836B (hu)
SG (2) SG121687A1 (hu)
SK (1) SK287339B6 (hu)
SV (1) SV2002000047A (hu)
TN (1) TNSN00064A1 (hu)
TR (1) TR200000837A2 (hu)
TW (1) TW553939B (hu)
UA (2) UA80955C2 (hu)
UY (1) UY26086A1 (hu)
YU (1) YU13200A (hu)
ZA (1) ZA200001586B (hu)

Families Citing this family (68)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6706721B1 (en) 1998-04-29 2004-03-16 Osi Pharmaceuticals, Inc. N-(3-ethynylphenylamino)-6,7-bis(2-methoxyethoxy)-4-quinazolinamine mesylate anhydrate and monohydrate
US7087613B2 (en) 1999-11-11 2006-08-08 Osi Pharmaceuticals, Inc. Treating abnormal cell growth with a stable polymorph of N-(3-ethynylphenyl)-6,7-bis(2-methoxyethoxy)-4-quinazolinamine hydrochloride
UA74803C2 (uk) * 1999-11-11 2006-02-15 Осі Фармасьютікалз, Інк. Стійкий поліморф гідрохлориду n-(3-етинілфеніл)-6,7-біс(2-метоксіетокси)-4-хіназолінаміну, спосіб його одержання (варіанти) та фармацевтичне застосування
ATE399766T1 (de) 2000-10-20 2008-07-15 Eisai R&D Man Co Ltd Stickstoff enthaltende aromatische heterozyklen
EP1408980A4 (en) 2001-06-21 2004-10-20 Ariad Pharma Inc NEW QUINAZOLINES AND THEIR USE
US7078409B2 (en) 2002-03-28 2006-07-18 Beta Pharma, Inc. Fused quinazoline derivatives useful as tyrosine kinase inhibitors
CA2491191C (en) 2002-07-15 2014-02-04 Exelixis, Inc. Receptor-type kinase modulators and methods of use
US7148231B2 (en) * 2003-02-17 2006-12-12 Hoffmann-La Roche Inc. [6,7-Bis(2-methoxy-ethoxy)-quinazolin-4-yl]-(3-ethynyl-phenyl)amine hydrochloride polymorph
EP1604665B1 (en) 2003-03-10 2011-05-11 Eisai R&D Management Co., Ltd. C-kit kinase inhibitor
US8309562B2 (en) * 2003-07-03 2012-11-13 Myrexis, Inc. Compounds and therapeutical use thereof
AU2004253967B2 (en) 2003-07-03 2010-02-18 Cytovia, Inc. 4-arylamino-quinazolines as activators of caspases and inducers of apoptosis
CA2538884C (en) 2003-09-16 2010-09-21 Astrazeneca Ab Quinazoline derivatives as tyrosine kinase inhibitors
ES2925655T3 (es) 2003-09-26 2022-10-19 Exelixis Inc Moduladores c-Met y métodos de uso
US7683172B2 (en) 2003-11-11 2010-03-23 Eisai R&D Management Co., Ltd. Urea derivative and process for preparing the same
PT1746999E (pt) * 2004-05-06 2012-01-11 Warner Lambert Co 4-fenilamino-quinazolin-6-il-amidas
KR20070053205A (ko) 2004-09-17 2007-05-23 에자이 알앤드디 매니지먼트 가부시키가이샤 의약 조성물
CA2592900A1 (en) 2005-01-03 2006-07-13 Myriad Genetics Inc. Nitrogen containing bicyclic compounds and therapeutical use thereof
US8258145B2 (en) 2005-01-03 2012-09-04 Myrexis, Inc. Method of treating brain cancer
US7625911B2 (en) * 2005-01-12 2009-12-01 Mai De Ltd. Amorphous form of erlotinib hydrochloride and its solid amorphous dispersion
EP1859793B1 (en) 2005-02-28 2011-04-20 Eisai R&D Management Co., Ltd. Novel combinational use of a sulfonamide compound in the treatment of cancer
WO2007015569A1 (ja) * 2005-08-01 2007-02-08 Eisai R & D Management Co., Ltd. 血管新生阻害物質の効果を予測する方法
EP1925676A4 (en) 2005-08-02 2010-11-10 Eisai R&D Man Co Ltd TEST METHOD FOR THE EFFECT OF A VASCULARIZATION INHIBITOR
AU2006309551B2 (en) * 2005-11-07 2012-04-19 Eisai R & D Management Co., Ltd. Use of combination of anti-angiogenic substance and c-kit kinase inhibitor
WO2007061130A1 (ja) * 2005-11-22 2007-05-31 Eisai R & D Management Co., Ltd. 多発性骨髄腫に対する抗腫瘍剤
EP2036557B1 (en) * 2006-05-18 2015-10-21 Eisai R&D Management Co., Ltd. Antitumor agent for thyroid cancer
JPWO2008001956A1 (ja) * 2006-06-29 2009-12-03 エーザイ・アール・アンド・ディー・マネジメント株式会社 肝線維症治療剤
WO2008012105A1 (en) 2006-07-28 2008-01-31 Synthon B.V. Crystalline erlotinib
WO2008026748A1 (fr) 2006-08-28 2008-03-06 Eisai R & D Management Co., Ltd. Agent antitumoral pour cancer gastrique non différencié
US8372856B2 (en) 2006-10-27 2013-02-12 Synthon Bv Hydrates of erlotinib hydrochloride
US20100048503A1 (en) 2007-01-19 2010-02-25 Eisai R & D Management Co., Ltd. Composition for treatment of pancreatic cancer
US8962655B2 (en) 2007-01-29 2015-02-24 Eisai R&D Management Co., Ltd. Composition for treatment of undifferentiated gastric cancer
EP2170844B1 (en) * 2007-02-21 2016-05-04 Natco Pharma Limited Novel polymorphs of erlotinib hydrochloride and method of preparation
KR101441930B1 (ko) 2007-04-04 2014-09-19 시플라 리미티드 에르로티닙 및 그의 약학적으로 허용가능한 염의 제조방법
US20090012295A1 (en) * 2007-06-25 2009-01-08 Ales Gavenda Amorphous Erlotinib, processes for the preparation thereof, and processes to prepare additional forms of Erlotinib
WO2009007984A2 (en) 2007-07-11 2009-01-15 Hetero Drugs Limited An improved process for erlotinib hydrochloride
WO2009025876A2 (en) * 2007-08-23 2009-02-26 Plus Chemicals, S.A. Crystalline forms of erlotinib hcl and formulations thereof
US20090124642A1 (en) * 2007-08-23 2009-05-14 Augusto Canavesi Crystalline forms of Erlotinib HCI and formulations thereof
US20090076042A1 (en) * 2007-09-15 2009-03-19 Protia, Llc Deuterium-enriched erlotinib
AU2008325608B2 (en) 2007-11-09 2013-03-14 Eisai R & D Management Co., Ltd. Combination of anti-angiogenic substance and anti-tumor platinum complex
EP2248804A4 (en) * 2008-01-29 2014-09-10 Eisai R&D Man Co Ltd COMBINED USE OF AN ANGIOGENESIS INHIBITOR AND A TAXANE
CN102083801A (zh) * 2008-03-28 2011-06-01 康瑟特制药公司 喹唑啉衍生物和治疗方法
WO2010005924A1 (en) * 2008-07-07 2010-01-14 Plus Chemicals Sa Crystalline forms of erlotinib base and erlotinib hcl
KR101132937B1 (ko) 2008-10-01 2012-04-06 주식회사종근당 Ｎ-(3-에티닐페닐)-6,7-비스(2-메톡시에톡시)-4-퀴나졸린아민 납실레이트 염
WO2010040212A1 (en) * 2008-10-08 2010-04-15 Apotex Pharmachem Inc. Processes for the preparation of erlotinib hydrochloride
TWI447108B (zh) 2009-01-16 2014-08-01 Exelixis Inc Ｎ－（４－｛〔６，７雙（甲氧基）喹啉－４－基〕氧基｝苯基）－ｎ’－（４－氟苯基）環丙烷－１，１－二甲醯胺之蘋果酸鹽及其結晶型
CN102438995B (zh) 2009-03-26 2014-12-17 兰贝克赛实验室有限公司 厄洛替尼或其药学上可接受的盐的制备工艺
UA108618C2 (uk) 2009-08-07 2015-05-25 Застосування c-met-модуляторів в комбінації з темозоломідом та/або променевою терапією для лікування раку
WO2011058525A2 (en) 2009-11-12 2011-05-19 Ranbaxy Laboratories Limited Processes for the preparation of erlotinib hydrochloride form a and erlotinib hydrochloride form b
WO2011068404A2 (en) 2009-12-02 2011-06-09 Ultimorphix Technologies B.V. Administration of n-(3-ethynylphenylamino)-6,7-bis(2- methoxyethoxy)-4-quinazolinamine mesylate salt by inhalation
ES2573515T3 (es) 2010-06-25 2016-06-08 Eisai R&D Management Co., Ltd. Agente antitumoral que emplea compuestos con efecto inhibitorio de cinasas combinados
AU2011298167B2 (en) 2010-07-23 2015-11-26 Generics [Uk] Limited Pure erlotinib
IT1402029B1 (it) 2010-10-14 2013-08-28 Italiana Sint Spa Procedimento per la preparazione di erlotinib
RU2580609C2 (ru) 2011-04-18 2016-04-10 Эйсай Ар Энд Ди Менеджмент Ко., Лтд. Противоопухолевое терапевтическое средство
ES2705950T3 (es) 2011-06-03 2019-03-27 Eisai R&D Man Co Ltd Biomarcadores para predecir y valorar la capacidad de respuesta de sujetos con cáncer de tiroides y de riñón a compuestos de lenvatinib
CN102267952B (zh) * 2011-06-21 2013-12-11 天津市汉康医药生物技术有限公司 喹唑啉类化合物、其制备方法和用途
CN103420924B (zh) * 2012-05-25 2016-08-31 浙江九洲药业股份有限公司 一种盐酸埃罗替尼晶型a的制备方法
WO2014037961A1 (en) 2012-09-04 2014-03-13 Shilpa Medicare Limited Crystalline erlotinib hydrochloride process
EP2937337A4 (en) 2012-12-21 2016-06-22 Eisai R&D Man Co Ltd AMORPHIC FORM OF CHINOLINE DERIVATIVES AND METHOD FOR THE PRODUCTION THEREOF
WO2014118737A1 (en) 2013-01-31 2014-08-07 Ranbaxy Laboratories Limited Erlotinib salts
NZ714049A (en) 2013-05-14 2020-05-29 Eisai R&D Man Co Ltd Biomarkers for predicting and assessing responsiveness of endometrial cancer subjects to lenvatinib compounds
CN103333124B (zh) * 2013-05-28 2015-03-25 埃斯特维华义制药有限公司 一种制备盐酸厄洛替尼晶型f的方法
TWI721954B (zh) 2014-08-28 2021-03-21 日商衛材R&D企管股份有限公司 高純度喹啉衍生物及其生產方法
CA2908441A1 (en) 2014-10-28 2016-04-28 Cerbios-Pharma Sa Process for the preparation of erlotinib
RU2017128583A (ru) 2015-02-25 2019-03-25 Эйсай Ар Энд Ди Менеджмент Ко., Лтд. Способ ослабления горечи хинолинового производного
CA2978226A1 (en) 2015-03-04 2016-09-09 Merck Sharpe & Dohme Corp. Combination of a pd-1 antagonist and a vegfr/fgfr/ret tyrosine kinase inhibitor for treating cancer
AU2016279474B2 (en) 2015-06-16 2021-09-09 Eisai R&D Management Co., Ltd. Anticancer agent
CN105884653A (zh) * 2016-06-08 2016-08-24 浙江汇能生物股份有限公司 一种埃罗替尼衍生物及其制备方法
CN106279585A (zh) * 2016-08-26 2017-01-04 宁波圣达精工智能科技有限公司 一种阻燃智能密集书架的制备方法

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4747498A (en) * 1986-06-27 1988-05-31 Sunbeam Plastics Corporation Safety dispensing closure-container package
AU661533B2 (en) * 1992-01-20 1995-07-27 Astrazeneca Ab Quinazoline derivatives
JP2657760B2 (ja) * 1992-07-15 1997-09-24 小野薬品工業株式会社 ４−アミノキナゾリン誘導体およびそれを含有する医薬品
DE69536015D1 (de) * 1995-03-30 2009-12-10 Pfizer Prod Inc Chinazolinone Derivate
US5747498A (en) * 1996-05-28 1998-05-05 Pfizer Inc. Alkynyl and azido-substituted 4-anilinoquinazolines
HUP9901155A3 (en) 1996-02-13 2003-04-28 Astrazeneca Ab Quinazoline derivatives as vegf inhibitors
KR100489174B1 (ko) 1996-03-05 2005-09-30 제네카-파마 소시에떼아노님 4-아닐리노퀴나졸린유도체
GB9718972D0 (en) 1996-09-25 1997-11-12 Zeneca Ltd Chemical compounds
US6225499B1 (en) 1997-07-14 2001-05-01 Catalytica Pharmaceuticals, Inc. Process for preparing aminoarylacetylenes
PL196940B1 (pl) 1998-04-29 2008-02-29 Osi Pharmaceuticals Bezwodna postać i monohydrat mesylanu N-(3-etynylofenylo)-6,7-bis (2-metoksyetoksy)-4-chinazolinaminy

Also Published As

Publication number Publication date
EP1044969B1 (en) 2006-12-13
IS2468B (is) 2008-12-15
PL339330A1 (en) 2000-10-09
CA2427221C (en) 2008-09-16
EA200000274A2 (ru) 2000-10-30
NO321952B1 (no) 2006-07-24
AU2005201494A1 (en) 2005-05-05
CR6165A (es) 2008-10-10
PA8491901A1 (es) 2001-12-14
AP1265A (en) 2004-03-26
HU227698B1 (en) 2011-12-28
ATE348098T1 (de) 2007-01-15
SK4442000A3 (en) 2000-10-09
GEP20022653B (en) 2002-03-25
AU2005201494B2 (en) 2008-02-07
CN1215061C (zh) 2005-08-17
CZ299426B6 (cs) 2008-07-23
DK1044969T3 (da) 2007-04-23
AP2000001778A0 (en) 2000-03-31
AU2262000A (en) 2000-10-05
CN1276370A (zh) 2000-12-13
KR100430210B1 (ko) 2004-05-03
EA005892B1 (ru) 2005-06-30
CA2302965C (en) 2004-02-17
YU13200A (sh) 2002-10-18
PT1044969E (pt) 2007-05-31
HUP0001353A3 (en) 2002-01-28
UA80955C2 (en) 2007-11-26
NO20001648D0 (no) 2000-03-30
OA11335A (en) 2003-12-10
IS5411A (is) 2000-10-02
KR20010014658A (ko) 2001-02-26
BG104278A (en) 2001-08-31
EP1044969A2 (en) 2000-10-18
EP1044969A3 (en) 2000-11-29
EA200201245A1 (ru) 2003-04-24
BR0001486A (pt) 2001-05-02
SG115536A1 (en) 2005-10-28
CA2427221A1 (en) 2000-09-30
JP3420549B2 (ja) 2003-06-23
ES2278578T3 (es) 2007-08-16
EE200000255A (et) 2000-12-15
PE20001599A1 (es) 2001-01-18
HRP20000182A2 (en) 2001-04-30
SG121687A1 (en) 2006-05-26
CA2302965A1 (en) 2000-09-30
MY136270A (en) 2008-09-30
NO324745B1 (no) 2007-12-03
TNSN00064A1 (fr) 2005-11-10
EE04589B1 (et) 2006-02-15
HRP20000182B1 (en) 2007-10-31
IL168036A (en) 2006-12-10
JP2000290262A (ja) 2000-10-17
ZA200001586B (en) 2001-10-01
DE60032275T2 (de) 2007-07-12
CN1699350A (zh) 2005-11-23
SK287339B6 (sk) 2010-07-07
NO20054715L (no) 2000-10-02
CZ20001155A3 (cs) 2001-03-14
EA005561B1 (ru) 2005-04-28
CO5160273A1 (es) 2002-05-30
BRPI0001486B1 (pt) 2019-01-29
IL135245A0 (en) 2001-05-20
HUP0001353A2 (hu) 2001-05-28
HK1029790A1 (en) 2001-04-12
NO20001648L (no) 2000-10-02
MA25087A1 (fr) 2000-10-01
TW553939B (en) 2003-09-21
KR100430209B1 (ko) 2004-05-03
BRPI0001486B8 (pt) 2021-05-25
TR200000837A2 (tr) 2000-11-21
EA200201244A1 (ru) 2003-04-24
KR20020084903A (ko) 2002-11-13
DE60032275D1 (de) 2007-01-25
NZ512818A (en) 2003-01-31
BG65194B1 (bg) 2007-06-29
CN100351242C (zh) 2007-11-28
HU0001353D0 (en) 2000-06-28
EA200000274A3 (ru) 2003-02-27
JP2003176274A (ja) 2003-06-24
UY26086A1 (es) 2000-10-31
US6476040B1 (en) 2002-11-05
SV2002000047A (es) 2002-01-23
GT200000037A (es) 2001-09-21
JP4074509B2 (ja) 2008-04-09
DZ3030A1 (fr) 2004-03-27
UA70928C2 (uk) 2004-11-15
AR018705A1 (es) 2001-11-28
AP1655A (en) 2006-09-01
NZ503683A (en) 2001-09-28
RS49836B (sr) 2008-08-07
ID25427A (id) 2000-10-05
AU781402B2 (en) 2005-05-19
EA004654B1 (ru) 2004-06-24

Similar Documents

Publication Publication Date Title
EG22506A (en) Processes and intermediates for preparing anti-cancer compounds
AP2003002757A0 (en) Process and intermediates for preparing anticancer compounds
IL145798A0 (en) Fap-activated anti-tumor compounds
EP1140083A4 (en) NEW CONNECTIONS
HUP0200448A3 (en) Processes for preparing pesticidal intermediates
GB9930390D0 (en) Releasable fasteners
EG24063A (en) Novel compounds
IL149007A0 (en) Pentacyclic taxane compounds
GB9924855D0 (en) Novel processes
IL146054A0 (en) Processes for preparing pesticidal intermediates
GB0121486D0 (en) Processes for the preparation of Α-Aminoketones
IL138691A (en) Process for the preparation of 3-acyl-indoles
HUP0202865A3 (en) Process for the preparation of 2-cyanopyridines
GB9923024D0 (en) Lap top extension
HUP0000559A3 (en) Process for preparing cyanoaceticacidesters
EP1242378A4 (en) NEW PROCEDURES
TW382910U (en) Structural improvement for the physique of the clog
GB0001064D0 (en) Structure for positioning stationery
IL140300A0 (en) Process for the preparation of amides
HU9904575D0 (en) Process for preparation of n-alkoxy-methyl-acidamides
TW404191U (en) Structure improvement for pendants
TW377550U (en) Improvement for grass-planting brick
HUP0201518A3 (en) Process for the preparation of tetrafluorohalogenbenzenes
TW385647U (en) Structure for ring
PL343301A1 (en) Fastening means